title: Human breath isoprene and its relation to blood cholesterol levels: new measurements and modeling.
abstract: Numerous publications have described measurements of breath isoprene in humans, and there has been a hope that breath isoprene analyses could be a noninvasive diagnostic tool to assess blood cholesterol levels or cholesterol synthesis rate. However, significant analytic problems in breath isoprene analysis and variability in isoprene levels with age, exercise, diet, etc., have limited the usefulness of these measurements. Here, we have applied proton transfer reaction-mass spectrometry to this problem, allowing on-line detection of breath isoprene. We show that breath isoprene concentration increases within a few seconds after exercise is started as a result of a rapid increase in heart rate and then reaches a lower steady state when breath rate stabilizes. Additional experiments demonstrated that increases in heart rate associated with standing after reclining or sleeping are associated with increased breath isoprene concentrations. An isoprene gas-exchange model was developed and shows excellent fit to breath isoprene levels measured during exercise. In a preliminary experiment, we demonstrated that atorvastatin therapy leads to a decrease in serum cholesterol and low-density-lipoprotein levels and a parallel decrease in breath isoprene levels. This work suggests that there is constant endogenous production of isoprene during the day and night and reaffirms the possibility that breath isoprene can be a noninvasive marker of cholesterologenesis if care is taken to measure breath isoprene under standard conditions at constant heart rate.
authors.affiliation: Institut für Ionenphysik, Universität Innsbruck, 6020 Innsbruck, Austria. thomas.karl@uibk.ac.at
authors.forename: T
authors.initials: T
authors.lastname: Karl
authors.forename: P
authors.initials: P
authors.lastname: Prazeller
authors.forename: D
authors.initials: D
authors.lastname: Mayr
authors.forename: A
authors.initials: A
authors.lastname: Jordan
authors.forename: J
authors.initials: J
authors.lastname: Rieder
authors.forename: R
authors.initials: R
authors.lastname: Fall
authors.forename: W
authors.initials: W
authors.lastname: Lindinger
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D001944:Breath Tests; D002070:Butadienes / Q000032:analysis*; D002784:Cholesterol / Q000097:blood*; D015444:Exercise / Q000502:physiology; D006339:Heart Rate / Q000502:physiology*; D045782:Hemiterpenes; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood; D013058:Mass Spectrometry / Q000379:methods; D008954:Models, Biological; D008991:Monitoring, Physiologic / Q000379:methods; D010420:Pentanes; D005082:Physical Exertion / Q000502:physiology; D011187:Posture; D011758:Pyrroles / Q000627:therapeutic use; D015656:Respiratory Mechanics / Q000502:physiology; D012890:Sleep / Q000502:physiology; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D002070:Butadienes; D045782:Hemiterpenes; D006538:Heptanoic Acids; D008077:Lipoproteins, LDL; D010420:Pentanes; D011758:Pyrroles; C005059:isoprene; D002784:Cholesterol; D000069059:Atorvastatin